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We conducted a case–control study of 18 US transplant re-
cipients with Rhodococcus infection and 36 matched controls. 
The predominant types of infection were pneumonia and bac-
teremia. Diabetes mellitus and recent opportunistic infection 
were independently associated with disease. Outcomes were 
generally favorable except for 1 relapse and 1 death.
Rhodococcus, a gram-positive coccobacillus, has been isolated from water, soil, and the manure of herbi-
vores. It is a facultative intracellular pathogen that survives 
in host macrophages. Immunosuppressive medications 
that compromise cell-mediated immunity can predispose 
to infection (1,2).
Our knowledge of disease characteristics among trans-
plant recipients is limited to case reports (3–8). With the 
increase in organ transplantation and improved survival of 
transplant recipients, the incidence of disease will likely 
increase in the coming years. In this study, we sought to 
describe characteristics, risk factors, and outcomes of Rho-
dococcus infection among solid organ transplant (SOT) 
and hematopoietic stem cell transplant (HSCT) recipients 
in the United States.
The Study
We conducted a case–control study at 8 US medical cen-
ters during January 2000–December 2012. The study was 
approved by appropriate Institutional Review Boards. Case-
patients were those with clinical or radiographic features of 
infection and positive culture results for Rhodococcus spp. 
Identification of the organism was performed by using bio-
chemical methods at microbiology laboratories of participat-
ing institutions. At the discretion of laboratory staff, identifi-
cation was confirmed by using 16S rRNA sequencing.
Controls received a similar organ within 3 months be-
fore or after the index case-patient at the same center and 
did not show Rhodococcus infection. Each case-patient was 
matched with 2 controls. Allogeneic and autologous HSCT 
recipients were matched to recipients of the same type.
We used descriptive statistics to summarize results 
for the cohort. Conditional logistic regression was used to 
evaluate risk factors for infection. Factors associated with 
disease less than the 0.10 significance level for univariate 
analysis were included in the multivariate model. Statisti-
cal software Stata/SE version 13.1 (StataCorp LP, College 
Station, TX, USA) was used.
We identified 18 patients with Rhodococcus spp. infec-
tion (Table 1, https://wwwnc.cdc.gov/EID/article/23/3/16-
0633-T1.htm). Mean age was 55 (range 3–78) years. Six 
patients underwent HSCT (5 allogeneic, 1 autologous) and 
12 SOT (4 heart, 4 lung, 3 kidney, 1 liver). Median time 
from transplant to infection was 5 (range 2–54) for HSCT 
recipients and 28 (range 3–237) months for SOT recipients. 
Infection occurred within the first year posttransplant for 
half of the patients. Five (39%) of 13 patients were living 
on a farm or had known contact with horses; exposure his-
tory was unknown for 5 patients.
Median time to diagnosis after onset of symptoms was 
20 (range 2–67) days. This median was determined mainly 
by the time that the patient sought medical attention and 
the time of clinical specimen collection. At the time of di-
agnosis, 3 (17%) patients were managed in outpatient set-
tings, 12 (67%) in inpatient wards, and 3 (17%) in inten-
sive care units.
The predominant infections were pneumonia (61%, 
11/18) and bacteremia (56%, 10/18). Bacteremia was sec-
ondary to pneumonia for 4 patients and catheter-associated 
for 4 patients. Fever occurred in half of the patients. Pa-
tients with pneumonia had dyspnea (45%, 5/11), cough 
(70%, 7/10), sputum production (20%, 2/10), and chest 
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pain (30%, 3/10). None had hemoptysis. Lung disease was 
infiltrative in 8/11 (73%) patients,  nodular in 8/11 (73%), 
and cavitary in 2/11 (18%). Median neutrophil count at 
diagnosis was 4,133/mm3 (range 532–16,468/mm3), and 
median lymphocyte count was 705/mm3 (range 90–3,350/
mm3). Species identification was performed for 9 isolates 
(8 R. equi and 1 R. corynebacterioides). We found no sig-
nificant difference in incidence of preceding opportunis-
tic infection between SOT and HSCT recipients (33% vs. 
50%; p = 0.62).
Infected patients were matched with 36 controls. Uni-
variate analysis showed that type of immunosuppression, 
augmented immunosuppression, increased levels of tacro-
limus or cyclosporine, and trimethoprim/sulfamethoxazole 
(TMP/SMX) prophylaxis were not associated with infec-
tion. Multivariate analysis showed that diabetes mellitus 
(p = 0.041) and recent opportunistic infection (p = 0.045) 
were independently associated with infection (Table 2).
All isolates tested were susceptible to vancomy-
cin (5/5), rifampin (5/5), linezolid (9/9), and imipenem 
(7/7). Fourteen percent (1/7) were susceptible to amoxi-
cillin/clavulanate; 29% (2/7) to ceftriaxone; 55% (6/11) 
to TMP/SMX; 70% (7/10) to tetracycline or minocycline; 
75% (6/8) to azithromycin or clarithromycin; and 80% 
(4/5) to levofloxacin, moxifloxacin, or gatifloxacin. Four 
isolates were resistant to penicillin and 1 was resistant 
to clindamycin.
Most patients received combination treatment with 
2–3 antimicrobial drugs (Table 1). Most commonly used 
drugs in the initial regimen were vancomycin, a fluoro-
quinolone, or a carbapenem. Median duration of treatment 
was 1 month (range 2 weeks–7 months) for patients with 
cathether-associated bacteremia and 6 months (range 2–60 
months) for patients with all other infections. Immunosup-
pression was decreased in 44% (7/16). The patient with a 
pacemaker pocket infection had the device removed.
Median follow-up period was 17 (range 1–84) months. 
One allogeneic HSCT recipient with R. equi pneumonia 
died of respiratory failure 13 days after diagnosis. He was 
receiving effective treatment with levofloxacin and TMP/
SMX. One allogeneic HSCT recipient with bacteremic 
cavitary pneumonia who received 6 months of antimicro-
bial drug treatment had disease relapse (fever, cough, and 
dyspnea) 9 months after initial presentation. Rhodococcus 
spp. were recovered from bronchoalveolar lavage fluid at 
relapse. The 4 patients with catheter-associated bacteremia 
had their catheters removed and did not show relapse.
Conclusions
Our study showed an association between Rhodococcus in-
fection and preceding opportunistic infection. This finding 
suggests that affected patients have a high net state of im-
munosuppression. Prior cytomegalovirus infection, the most 
common opportunistic infection in the study, might have had 
an immunomodulatory effect that made patients more likely 
to show development of a second opportunistic infection.
Most patients were not neutropenic at diagnosis, con-
sistent with the fact that Rhodococcus spp. affect mainly 
patients with impaired cell-mediated immunity. TMP/
SMX prophylaxis did not confer protection, probably be-
cause of high resistance rates. Patients did not always have 
a history of exposure to livestock as previously described 
(2). Median time to infection was shorter for HSCT re-
cipients, probably because catheter-associated bacteremia  
 
 
Table 2. Univariate analysis of risk factors associated with Rhodococcus infection in solid organ and hematopoietic stem cell 
transplant recipients, United States* 
Variable Case-patients, n = 18 Control patients, n = 36 Univariate OR (95% CI)  p value 
Mean age, y (range) 55 (3–78) 50 (2–78) 1.05 (0.99–1.11) 0.13 
Male sex 12/18 (66.7) 22/36 (61.1) 1.21 (0.42–3.45) 0.72 
White race 15/18 (83.3) 23/36 (63.9) 3.17 (0.65–15.43) 0.15 
Diabetes mellitus† 9/18 (50.0) 6/34 (17.6) 9.90 (1.20–81.62) 0.03 
Chronic kidney disease‡ 3/16 (18.8) 5/35 (14.3) 1.15 (0.19–7.03) 0.88 
Immunosuppressant     
 Tacrolimus 10/18 (55.6) 25/35 (71.4) 0.15 (0.02–1.39) 0.10 
 Sirolimus 3/18 (16.7) 2/35 (5.7) 4.65 (0.46–46.89) 0.19 
 Mycophenolate mofetil 10/18 (55.6) 18/35 (5.4) 1.36 (0.20–9.0) 0.75 
 Prednisone 13/18 (72.2) 25/35 (71.4) 1.00 (0.25–4.0) 1.00 
 Cyclosporine 2/18 (11.1) 3/35 (8.6) 2.00 (0.13–31.98) 0.62 
Increased calcineurin inhibitor level§ 2/13 (15.4) 4/32 (13.3) 1.20 (0.16–9.20) 0.86 
History of allograft rejection 2/12 (16.7) 1/24 (4.2) 4.00 (0.36–44.11) 0.26 
Augmented immunosuppression¶ 7/18 (38.9) 13/37 (35.1) 1.28 (0.24–6.89) 0.77 
TMP/SMX prophylaxis 10/18 (55.6) 19/36 (52.7) 1.15 (0.33–4.03) 0.83 
History of opportunistic infection# 7/18 (38.9) 4/36 (11.1) 10.57 (1.25–89.0) 0.03 
*Values are no. (%) unless otherwise indicated. OR, odds ratio; TMP/SMX, trimethoprim/sulfamethoxazole. 
†Requiring treatment with oral antidiabetic agent(s) or insulin. 
‡Creatinine level >2 mg/dL. 
§Tacrolimus >12 g/mL or cyclosporine >250 g/mL in the preceding 30 days. 
¶Use of corticosteroid pulses, alemtuzumab, anti-thymocyte globulin, basiliximab, or rituximab in the 6 months preceding infection. 
#Opportunistic infections in case-patients were cytomegalovirus viremia (3) or invasive disease (2), pulmonary aspergillosis (1), and BK polyomavirus–
associated hemorrhagic cystitis (1). 
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was more common among these patients. Predominantly 
among SOT recipients, infection occurred late after trans-
plant (>12 months), and none of the infections were cath-
eter-associated (2).
For systemic infections, monotherapy might result in 
emergence of resistance. In a report from Taiwan, 3 of 7 
R. equi isolates had inherent concomitant resistance to all 
β-lactams, macrolides, and rifampin (9). We did not observe 
this multidrug-resistance pattern. For transplant recipients 
with systemic infection, we recommend combination treat-
ment with 2–3 antimicrobial drugs (vancomycin, fluoro-
quinolone, or carbapenem). TMP/SMX and clindamycin 
should be avoided in empiric treatment regimens because 
of variable rates of susceptibility. Macrolide antimicrobial 
drugs, except for azithromycin, decrease the metabolism 
of cyclosporine, tacrolimus, sirolimus, and everolimus. 
Conversely, rifampin increases the metabolism of these 
drugs. These interactions should be considered when treat-
ing transplant recipients. Rhodococcus spp. can also form 
adherent biofilms (10). Thus, removal of central catheters 
is imperative in the management of infected patients.
We observed only 1 death attributable to infection in 
an HSCT recipient. This finding differs from an attributable 
mortality rate of 34.3% in a multicenter study of 67 patients 
with AIDS (mean CD4 cell count 35/µL) (11). The higher 
mortality rate probably reflects the degree of immunosup-
pression among patients with advanced HIV infection and 
close clinical monitoring of transplant recipients, which en-
ables timely management. Death and relapse rates in our se-
ries were comparable with those in a review of 30 cases (2).
Our retrospective study had inherent limitations relat-
ed to collection of data. In the analysis, we included SOT 
and HSCT recipients who differed in underlying disease 
states and immunosuppression. The study was also lim-
ited by the relatively small number of cases. This limita-
tion was also reflected in wide CIs in risk factor analysis. 
However, we showed that risk factors for Rhodococcus 
infection were diabetes mellitus and recent opportunistic 
infection. Outcomes were generally favorable after appro-
priate and timely treatment.
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